Physician profile
Matthew Marshall
NPI 1184936353
$1,831.20
in general payments reported to CMS, 2019-2025
14 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $30.00 · 2021: $189 · 2022: $127 · 2023: $280 · 2024: $265 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928 · Entertainment: $14.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.30 |
| Entertainment | $14.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $854.19 | 2019-2025 | Precision7, Rocklatan |
| Abbvie INC. | $336.02 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $212.07 | 2019-2023 | |
| Biotissue Holdings INC. | $97.47 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $61.91 | 2019-2025 | |
| Oyster Point Pharma, INC. | $44.59 | 2022-2023 | Tyrvaya |
| Allergan, INC. | $37.52 | 2021 | |
| Amgen INC. | $33.77 | 2025 | Tepezza |
| Thea Pharma INC. | $32.21 | 2024-2025 | Iyuzeh |
| Optos, INC. | $28.72 | 2021-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Dompe US, INC. | $27.82 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.25 | 2019 | |
| Bausch & Lomb Americas INC. | $21.98 | 2024 | Vyzulta |
| Shire North American Group INC | $20.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.